Novel targets and therapies of metformin in dementia: old drug, new insights.
| Autor: | Cui W; College of Life Sciences, Northwest University, Xi'an, China.; Department of Neurosurgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, China., Lv C; Hangzhou Simo Co., Ltd., Hangzhou, China., Geng P; College of Life Sciences, Northwest University, Xi'an, China., Fu M; College of Life Sciences, Northwest University, Xi'an, China., Zhou W; College of Life Sciences, Northwest University, Xi'an, China., Xiong M; College of Life Sciences, Northwest University, Xi'an, China., Li T; School of Basic Medicine, Fourth Military Medical University, Xi'an, China. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Frontiers in pharmacology [Front Pharmacol] 2024 May 31; Vol. 15, pp. 1415740. Date of Electronic Publication: 2024 May 31 (Print Publication: 2024). |
| DOI: | 10.3389/fphar.2024.1415740 |
| Abstrakt: | Dementia is a devastating disorder characterized by progressive and persistent cognitive decline, imposing a heavy public health burden on the individual and society. Despite numerous efforts by researchers in the field of dementia, pharmacological treatments are limited to relieving symptoms and fail to prevent disease progression. Therefore, studies exploring novel therapeutics or repurposing classical drugs indicated for other diseases are urgently needed. Metformin, a first-line antihyperglycemic drug used to treat type 2 diabetes, has been shown to be beneficial in neurodegenerative diseases including dementia. This review discusses and evaluates the neuroprotective role of metformin in dementia, from the perspective of basic and clinical studies. Mechanistically, metformin has been shown to improve insulin resistance, reduce neuronal apoptosis, and decrease oxidative stress and neuroinflammation in the brain. Collectively, the current data presented here support the future potential of metformin as a potential therapeutic strategy for dementia. This study also inspires a new field for future translational studies and clinical research to discover novel therapeutic targets for dementia. Competing Interests: Author CL was employed by Hangzhou Simo Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Cui, Lv, Geng, Fu, Zhou, Xiong and Li.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|